Program

FRIDAY, APRIL 17, 2020

7:45 a.m.	Registration/Exhibits/Continental Breakfast
8:15	INTRODUCTION AND WELCOME
8:25	GENETICS IN ONCOLOGY CARE Maureen Mork, MS, CGC
	wauteen work, wis, CGC
9:05	CANCER PREVENTION FOR HEREDITARY CANCERS
	Nadine Rayes, MS, CGC
	Banu Arun, MD
	Karen Lu, MD
	Y. Nancy You, MD
9:35	INTEGRATING GENETICS EVALUATION INTO CANCER SURVIVORSHIP CARE
	Ashley Anderson, RN, MSN, WHNP-BC
9:45	FAMILY HISTORY COLLECTION IN THE CLINICAL SETTING
	Victoria (Tori) McClosky, BSN, RN
9:55	Break
10:10	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS:
	SYSTEMIC THERAPY FOR BREAST CANCER
	Rachel Layman, MD
10:40	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS:
	SYSTEMIC THERAPY FOR OVARIAN CANCER
	Larissa Meyer, MD
11:10	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS:
	IMMUNOTHERAPY FOR COLORECTAL CANCER
	Kanwal Raghav, MD
11:40	Lunch (provided)
	•

12:30 p.m.	GENETICS IN THE PEDIATRIC AND YOUNG ADULT POPULATION Jessica Corredor, MS, CGC
	Michael Roth, MD
1:10	UPDATES ON HEREDITARY POLYPOSIS
	Julie Moskowitz, MS, CGC
	Selvi Thirumurthi, MD
1:50	Break
2:05	INTEGRATING UNIVERSAL GERMLINE
	GENETIC TESTING INTO CLINICAL PRACTICE
	Meagan Kaulfus, MS, CGC
2:20	ALTERNATIVE SERVICE DELIVERY MODELS IN ONCOLOGY GENETICS
	Kate Principe, MS, CGC
	Rachel Bluebond, MMSc, CGC
2:50	POLYGENIC RISK SCORES:
	CALCULATIONS AND USE IN CLINICAL MANAGEMENT
	Christopher Amos, MD
3:50	CLOSING REMARKS
	Karen Lu, MD
	Karen Lu, wiD
4:00	Adjourn



SATURDAY, APRIL 18, 2020

8:00 a.m.	Registration/Exhibits/Continental Breakfast
8:30	WELCOME Rachel Bluebond, MMSC, CGC
8:40	GENETIC TESTING TECHNOLOGIES: SOMATIC TESTING, GERMLINE TESTING, AND DIRECT-TO-CONSUMER TESTING Molly Daniels, MS, CGC
9:40	FERTILITY PRESERVATION IN ONCOLOGY CARE Terry Woodard, MD
10:00	Break
10:15	PREIMPLANTATION GENETIC SCREENING FOR HEREDITARY CANCER Sandra Darilek, MS, CGC
10:45	EXPERT REVIEW PANEL: SUBMITTED CASES DISCUSSED Rachel Bluebond, MMSc, CGC; Maureen Mork, MS, CGC; Julie Moskowitz, MS, CGC; Grace Tran, MS, CGC
11:25	PATIENT EXPERIENCE: LIFE AFTER GENETIC TESTING Bryan Joyce
11:45	CLOSING REMARKS Y. Nancy You, MD
noon	Adjourn

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.